Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the details of Analyst/ Institutional Investor/ Broker meeting to be conducted on 23rd August, 2022. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities & Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015, we enclose a copy of the newspaper clipping of Notice which appeared on 19th August, 2022, in the Business Standard- English daily and Mumbai Lakshadeep - Marathi daily in respect of the corrigendum to notice of the 48th Annual General Meeting of the Company. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Retirement
Pursuant to Regulation 30(2) read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Mr. Balmiki Prasad Singh (DIN 00739856) has informed the Company on 17th August, 2022 about his unwillingness to offer himself for re-appointment at the Annual General Meeting of the Company scheduled to be held on 25th August, 2022 on grounds of his health and thereby intends to retire from the position of an Executive Director on the Board of Directors of the Company. Accordingly, Mr. Balmiki Prasad Singh shall retire upon conclusion of the ensuing Annual General Meeting. The requisite disclosure as required under regulation 30 read with Schedule III, Para A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/CMD/4/2015 dated 30th September, 2015 is attached as ''Annexure I''. Kindly take the same on your records. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached schedule of Analyst/Institutional Investor meeting with the Company. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We enclose herewith the transcript of the "Q1 FY2023 Earnings Conference Call" which was hosted by the Company on Friday, 05th August, 2022. The said transcript shall also be made available on the website of the Company. Kindly take the same on record. Cell therapy company Eyestem raises 51 crore in funding
Three pharma companies-Biological E. Ltd, Alkem, NATCO, andAnurag and Karan Bagaria,promotersof Kemwell Biopharmaled the Series A round funding Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the 'Q1FY23 Earnings Conference Call' is available on the website of the Company at https://www.alkemlabs.com/earnings-call.php Kindly take the same on record.
Results Earnings Call for Q1FY23 of Alkem Laboratories
Conference Call with Alkem Laboratories Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Change in Directorate
Please find attached herewith the revised disclosure for appointment of Mr. Sujjain Talwar (DIN: 01756539) as an Additional Director, designated as an Independent Director on the Board of Directors of the Company for a period of five (5) consecutive years with effect from 05th August, 2022 upto 04th August, 2027. Necessary particulars in relation to the said appointment, are included in Annexure I. We also confirm that Mr. Sujjain Talwar is not debarred from holding office of director by virtue of any SEBI order or any other such authority. Kindly take the same on your records. Q1FY23 Quarterly Result Announced for Alkem Laboratories Ltd.
Pharmaceuticals firm Alkem Laboratories Announced Q1FY23 Result : Total Revenue from Operations was Rs 25,764 million, YoY decline of 5.7% India sales were Rs 17,815 million, YoY decline of 6.7% International sales were Rs 7,604 million, YoY decline of 3.8% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 2,032 million, resulting in EBITDA margin of 7.9% vs. 21.7% in Q1FY21. EBITDA declined by 65.7% YoY R&D; expenses for the quarter was Rs 1,320 million, or 5.1% of total revenue from operations compared to Rs 1,183 million in Q1FY22 at 4.3% of total revenue from operations Profit before tax (PBT) was Rs 1,519 million, a decline of 72.7% compared to Q1FY22 Net Profit (after Minority Interest) was Rs 1,276 million, YoY decline of 72.7% Commenting on the results, Sandeep Singh, Managing Director, Alkem said, “We are starting the new fiscal year on a positive note, with yet another market beating performance in domestic market adjusting for huge base of last year [CAGR of 13.4%, Q1FY20-Q1FY23]. However, headwinds from price erosion in US market and inflationary environment has impacted margins for the quarter. As we move ahead, we remain focused on our journey of expanding margins through productivity improvement and various cost optimization initiatives across the organization. Our biosimilar franchise is shaping up well and we are looking forward to some exciting launches going ahead.” Result PDF